Saizen® + Saizen®
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Small Gestational Age (SGA)
Conditions
Small Gestational Age (SGA)
Trial Timeline
Feb 28, 2005 → Sep 30, 2007
NCT ID
NCT00249821About Saizen® + Saizen®
Saizen® + Saizen® is a phase 3 stage product being developed by Merck for Small Gestational Age (SGA). The current trial status is completed. This product is registered under clinical trial identifier NCT00249821. Target conditions include Small Gestational Age (SGA).
What happened to similar drugs?
20 of 20 similar drugs in Small Gestational Age (SGA) were approved
Approved (20) Terminated (2) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01746862 | Phase 3 | Completed |
| NCT00249821 | Phase 3 | Completed |
Competing Products
20 competing products in Small Gestational Age (SGA)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-1769 | Moderna | Phase 2 | 0 |
| BBP-398 with nivolumab | BridgeBio Pharma | Phase 1 | 18 |
| Pemetrexed + Carboplatin | Eli Lilly | Phase 3 | 40 |
| Necitumumab + Gemcitabine + Carboplatin | Eli Lilly | Phase 2 | 27 |
| Selpercatinib | Eli Lilly | Pre-clinical | 26 |
| Pemetrexed + Cisplatin + Placebo + Pemetrexed | Eli Lilly | Phase 3 | 40 |
| NBTXR3 | Nanobiotix | Phase 1/2 | 33 |
| Pemetrexed | Eli Lilly | Pre-clinical | 26 |
| pemetrexed + erlotinib | Eli Lilly | Phase 2 | 35 |
| LY3295668 Erbumine | Eli Lilly | Phase 1 | 29 |
| FYB206 + FYB206 + Keytruda | Formycon AG | Phase 3 | 22 |
| 6-Thio-2'-Deoxyguanosine + Cemiplimab | MAIA Biotechnology | Phase 2 | 32 |
| 6-Thio-2'-Deoxyguanosine + Cemiplimab + Docetaxel + Vinorelbine + Gemcitabine alone | MAIA Biotechnology | Phase 3 | 37 |
| pemetrexed + cisplatin | Eli Lilly | Phase 2 | 27 |
| gemcitabine + carboplatin + cisplatin | Eli Lilly | Phase 2 | 35 |
| Cetuximab | Eli Lilly | Phase 1 | 29 |
| pemetrexed + docetaxel | Eli Lilly | Phase 3 | 40 |
| enzastaurin + pemetrexed + docetaxel + carboplatin | Eli Lilly | Phase 2 | 35 |
| PemCarbo + Pem only | Eli Lilly | Phase 3 | 36 |
| TNG456 + abemaciclib | Eli Lilly | Phase 1/2 | 39 |